Drug Trial Radar · NCT00024427
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Jun 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Feb 2001
Primary completion
Feb 2006
Sponsor
- Lead sponsor
- Wellstat TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is more effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus triacetyluridine with that of gemcitabine in treating patients who have locally advanced or metastatic pancreatic cancer that cannot be treated with surgery.
Conditions
- Drug/Agent Toxicity by Tissue/Organ
- Pancreatic Cancer
Interventions
fluorouracilDrug
High dose 5-FU
gemcitabine hydrochlorideDrug
Normal dose to treat pancreatic cancer
triacetyluridineDrug
6 grams (12 tablets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer PatientsTime frame: Disease progression
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
Brookwood Medical Center
Birmingham, Alabama
Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama
Providence Saint Joseph Medical Center - Burbank
Burbank, California
City of Hope Comprehensive Cancer Center
Duarte, California
Scripps Cancer Center at Scripps Clinic
La Jolla, California
Northwest Oncology and Hematology Associates
Coral Springs, Florida
Florida Cancer Specialists - World Plaza
Fort Myers, Florida
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida
Florida Oncology Associates - South Side
Jacksonville, Florida
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Florida Cancer Institute - New Port Richey
New Port Richey, Florida
St. Joseph's Hospital
Savannah, Georgia
Cancer Care Center
New Albany, Indiana
Cancer Center at Greater Baltimore Medical Center
Baltimore, Maryland
Wellstat Therapeutics
Gaithersburg, Maryland
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota
Capitol Comprehensive Cancer Care Clinic
Jefferson City, Missouri
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico
Queens Medical Associates, PC
Fresh Meadows, New York
New York Weill Cornell Cancer Center at Cornell University
New York, New York
Summit Oncology Associates
Akron, Ohio
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania
Fox Chase - Temple Cancer Center
Philadelphia, Pennsylvania
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina
Corpus Christi Cancer Center
Corpus Christi, Texas
Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Regional Cancer Care at Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
McGill Cancer Centre at McGill University
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.